LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Fechado

SetorSaúde

68.68 1.87

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

66.54

Máximo

69.15

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	23.663 49.701
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+23.22% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	349M 8B
Abertura anterior	66.81
Fecho anterior	68.68

Sentimento de Notícias

By Acuity

38%

62%

157 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

60.49 / 70.14 Suporte e Resistência

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de mai. de 2026, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 de mai. de 2026, 22:02 UTC

Ganhos

ZTO Express (Cayman): Di Xu to Resign From Board

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 de mai. de 2026, 22:00 UTC

Ganhos

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 de mai. de 2026, 21:37 UTC

Ganhos

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 de mai. de 2026, 21:01 UTC

Ganhos

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 de mai. de 2026, 20:58 UTC

Ganhos

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 de mai. de 2026, 20:46 UTC

Ações em Alta

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 de mai. de 2026, 20:43 UTC

Conversa de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 de mai. de 2026, 20:34 UTC

Ganhos

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q EPS 5c >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q Sales $1.4B >JHX

19 de mai. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5B

19 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 de mai. de 2026, 19:23 UTC

Conversa de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

23.22% parte superior

Previsão para 12 meses

Média 83.1 USD 23.22%

Máximo 96 USD

Mínimo 66.41 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

60.49 / 70.14Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimento

By Acuity

157 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.